![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, June 12, 2015 1:24:45 AM
$PMCB recent news/filings
## source: finance.yahoo.com
Wed, 10 Jun 2015 15:32:21 GMT ~ PharmaCyte Biotech Officers to Attend 2015 BIO International Convention
[at noodls] - SILVER SPRING, Md., June 10, 2015 (GLOBE NEWSWIRE) - PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its ...
read full: http://www.noodls.com/view/EF8BED8BC929EC1BB91625DFBA3481B4DE3FA757
*********************************************************
Wed, 10 Jun 2015 13:25:00 GMT ~ PharmaCyte Biotech Officers to Attend 2015 BIO International Convention
[GlobeNewswire] - SILVER SPRING, Md., June 10, 2015-- PharmaCyte Biotech, Inc., a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation ...
read full: http://finance.yahoo.com/news/pharmacyte-biotech-officers-attend-2015-132500176.html
*********************************************************
Tue, 09 Jun 2015 19:37:10 GMT ~ PharmaCyte Biotech’s Contract Research Organization Voted Australia’s Favorite CRO for 2015
[at noodls] - SILVER SPRING, MD, June 9, 2015 (GLOBE NEWSWIRE) - PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using ...
read full: http://www.noodls.com/view/C877F762202014BEEC6E4CB25879BADDF091CF31
*********************************************************
Tue, 09 Jun 2015 13:25:00 GMT ~ PharmaCyte Biotech’s Contract Research Organization Voted Australia’s Favorite CRO for 2015
[GlobeNewswire] - SILVER SPRING, Md., June 09, 2015-- PharmaCyte Biotech, Inc., a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation ...
read full: http://finance.yahoo.com/news/pharmacyte-biotech-contract-research-organization-132500498.html
*********************************************************
Wed, 03 Jun 2015 13:30:00 GMT ~ PharmaCyte Biotech's Cancer Treatment Shows "Complete Tumor Remission" in Published Preclinical Study
[Marketwired] - PharmaCyte Biotech’s signature live-cell encapsulation technology, Cell-in-a-Box®, was the star of the show in a recently released corporate video by the company. In that video, PharmaCyte revealed that ...
read full: http://finance.yahoo.com/news/pharmacyte-biotechs-cancer-treatment-shows-133000454.html
*********************************************************
$PMCB charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$PMCB company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/PMCB/company-info
Ticker: $PMCB
OTC Market Place: OTCQB
CIK code: 0001157075
Company name: PharmaCyte Biotech, Inc.
Company website: http://www.PharmaCyteBiotech.com
Incorporated In: NV, USA
Business Description: PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box�. This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. PharmaCyte Biotech's treatment for pancreatic cancer involves low doses of the well-known anticancer prodrug ifosfamide, together with encapsulated live cells, which convert ifosfamide into its active or \"cancer-killing\" form. These capsules are placed as close to the cancerous tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer. This \"targeted chemotherapy\" has proven remarkably effective in past clinical trials. PharmaCyte Biotech is also working towards improving the quality of life for patients with advanced pancreatic cancer and on treatments for other types of solid cancerous tumors. In addition, PharmaCyte Biotech is developing treatments for cancer based upon chemical constituents of the Cannabis plant, known as cannabinoids. In doing so, PharmaCyte Biotech is examining ways to exploit the benefits of Cell-in-a-Box� technology in optimizing the anticancer effectiveness of cannabinoids, while minimizing or outright eliminating the debilitating side effects usually associated with cancer treatments. This provides PharmaCyte Biotech the rare opportunity to develop ?green? approaches to fighting deadly diseases, such as cancer of the pancreas, brain and breast, which affect hundreds of thousands of individuals worldwide every year.Less >>
$PMCB share structure
## source: otcmarkets.com
Market Value: $97,318,097 a/o Jun 11, 2015
Shares Outstanding: 707,767,981 a/o Mar 13, 2015
Float: 529,206,849 a/o Aug 26, 2014
Authorized Shares: 1,490,000,000 a/o Aug 26, 2014
Par Value: 0.0001
$PMCB extra dd links
Company name: PharmaCyte Biotech, Inc.
Company website: http://www.PharmaCyteBiotech.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=PMCB+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=PMCB+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=PMCB+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/PMCB/news - http://finance.yahoo.com/q/h?s=PMCB+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/PMCB/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/PMCB/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=PMCB+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/PMCB
DTCC (dtcc.com): http://search2.dtcc.com/?q=PharmaCyte+Biotech%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=PharmaCyte+Biotech%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=PharmaCyte+Biotech%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.PharmaCyteBiotech.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.PharmaCyteBiotech.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.PharmaCyteBiotech.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/PMCB
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001157075&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/PMCB/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/PMCB/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=PMCB&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=PMCB
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/PMCB/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=PMCB+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=PMCB+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=PMCB
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=PMCB
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=PMCB+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/PMCB/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=PMCB+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/PMCB.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=PMCB
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/PMCB/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/PMCB
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/PMCB
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/PMCB:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=PMCB
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=PMCB
Recent PMCB News
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 08:05:04 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 05/30/2024 08:05:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 08:40:20 PM
- PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease • Business Wire • 05/21/2024 01:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:38:38 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 02:56:28 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/15/2023 10:25:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/24/2023 09:00:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:02:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:02:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:00:10 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 11/22/2023 09:00:15 PM
- PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc. • Business Wire • 11/15/2023 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 10:25:09 PM
- PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology • Business Wire • 10/31/2023 01:15:00 PM
- PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology • Business Wire • 10/31/2023 01:15:00 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 09/21/2023 09:04:07 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 09/18/2023 10:04:06 AM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 09/15/2023 09:00:03 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 09/12/2023 01:56:25 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM